Aleta Biotherapeutics
Aleta Biotherapeutics is pioneering transformation of cancer treatment by enabling CAR T cancer therapies to work more effectively. The Company’s portfolio of multi-antigen CAR T Engagers (CTEs) are simple, biologics designed to enhance the expression of CAR T target antigen in any tumor cell. Their innovative biologics, such as ALETA-001, are in clinical trials and aim to improve outcomes for patients with blood cancers and solid tumors by increasing cancer target density, preventing resistance and escape, and enhancing the speed and effectiveness of CAR T cell therapies.
Industries
Nr. of Employees
small (1-50)
Aleta Biotherapeutics
Products
ALETA-001
A multispecific CAR-T engager biologic designed to present a CAR-recognized extracellular antigen domain on tumor cells via binding to a second tumor antigen, with the aim of restoring or increasing CAR target density. Evaluated in a Phase I/II clinical trial in patients previously treated with CD19-directed CAR-T therapy; reported regulatory interactions include innovation pathway designation and clinical trial authorization.
ALETA-004
A preclinical multi-antigen binding engager designed to bind multiple acute myeloid leukemia antigens and link them to a CAR-recognized antigen domain to enable CAR-T cell recognition of AML cells.
ALETA-005
A discovery-stage engager designed to present multiple target binding sites recognized by BCMA-directed CAR-T cells to augment CAR-T engagement in multiple myeloma.
Solid tumor multispecific engagers (discovery/preclinical)
Discovery-stage multispecific engager designs intended to connect validated solid tumor antigens to CAR-recognized antigen domains to recruit CAR-T cells to non-B cell cancers.
ALETA-001
A multispecific CAR-T engager biologic designed to present a CAR-recognized extracellular antigen domain on tumor cells via binding to a second tumor antigen, with the aim of restoring or increasing CAR target density. Evaluated in a Phase I/II clinical trial in patients previously treated with CD19-directed CAR-T therapy; reported regulatory interactions include innovation pathway designation and clinical trial authorization.
ALETA-004
A preclinical multi-antigen binding engager designed to bind multiple acute myeloid leukemia antigens and link them to a CAR-recognized antigen domain to enable CAR-T cell recognition of AML cells.
ALETA-005
A discovery-stage engager designed to present multiple target binding sites recognized by BCMA-directed CAR-T cells to augment CAR-T engagement in multiple myeloma.
Solid tumor multispecific engagers (discovery/preclinical)
Discovery-stage multispecific engager designs intended to connect validated solid tumor antigens to CAR-recognized antigen domains to recruit CAR-T cells to non-B cell cancers.
Services
Collaborative development partnerships
Partnered R&D and co-development arrangements to advance engager biologics into preclinical and clinical development, including collaborations with clinical sponsors and academic trial networks.
Preclinical and translational research support
Design and execution of in vitro and in vivo studies, assay development (binding, cytotoxicity, antigen-density and imaging assays), and biomarker analysis to support IND-enabling packages.
Clinical development and trial execution support
Support for design and operational execution of early-phase clinical studies for engager biologics, including regulatory interface, clinical operations and provision of GMP clinical supply.
Collaborative development partnerships
Partnered R&D and co-development arrangements to advance engager biologics into preclinical and clinical development, including collaborations with clinical sponsors and academic trial networks.
Preclinical and translational research support
Design and execution of in vitro and in vivo studies, assay development (binding, cytotoxicity, antigen-density and imaging assays), and biomarker analysis to support IND-enabling packages.
Clinical development and trial execution support
Support for design and operational execution of early-phase clinical studies for engager biologics, including regulatory interface, clinical operations and provision of GMP clinical supply.
Expertise Areas
- Multispecific engager biologics design
- Immune-synapse engineering for T cell activation
- Antigen-display platforms to restore or increase CAR target density
- Preclinical assay development and in vitro/in vivo models for engager validation
Key Technologies
- Multispecific/bispecific fusion proteins
- Immune synapse engineering
- Costimulatory-domain mimetics (CD2/CD58, CD28/B7-like modules)
- Antigen-display engager platforms